Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.8250
-0.0455 (-5.23%)
At close: Dec 5, 2025, 4:00 PM EST
0.8800
+0.0550 (6.67%)
After-hours: Dec 5, 2025, 7:59 PM EST
Salarius Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
4.84M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLRX News
- 5 days ago - Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewsWire
- 16 days ago - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewsWire
- 23 days ago - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewsWire
- 25 days ago - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - PRNewsWire
- 7 weeks ago - Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 4 months ago - Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 5 months ago - Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard - GlobeNewsWire